MUMBAI, India, June 30 -- Intellectual Property India has published a patent application (202527093437 A) filed by Jiangsu Hengrui Pharmaceuticals Co. , Ltd.; and Shanghai Hengrui Pharmaceutical Co. , Ltd. on September 29, 2025, for Antigen Binding Molecule Specifically Binding To Egfr And Muc1, Drug Conjugate Thereof, And Medical Use Thereof.
Inventors include Liu, Ziheng; Hu, Bing; Sun, Le; Liu, Shimeng; Gao, Xinyu; Li, Xun; Cao, Liqun; Ye, Xin; and He, Feng.
The application for the patent was published on June 26, 2026, under issue no. 26/2026.
Abstract: The present invention relates to an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof. Specifically, the present invention relates to an anti-MUC1 antibody or an antigen binding fragment thereof, an anti-EGFR antibody or an antigen binding fragment thereof, an antigen binding molecule specifically binding to EGFR and MUC1, a drug conjugate thereof, and a medical use thereof.
Disclaimer: Curated by HT Syndication.
